Literature DB >> 11162566

Interaction of hnRNP A2/B1 isoforms with telomeric ssDNA and the in vitro function.

H Kamma1, M Fujimoto, M Fujiwara, M Matsui, H Horiguchi, M Hamasaki, H Satoh.   

Abstract

Overexpression of heterogeneous nuclear ribonucleoprotein (hnRNP) A2/B1, especially of B1 has been reported as a useful marker to detect cancers in early stage, although the biological reason is not clear. A2/B1 proteins were previously reported to bind telomeric DNA repeats. Alternative splicing of A2/B1 gene produces abundant A2, less abundant B1, and testis-specific minor isoforms B0a and B0b. In this study, B1 and B0b that have the N-terminal 12 amino acid insertion were suggested to have higher affinities to telomeric single-stranded DNA (ssDNA) than A2 and B0a. Kinetic analyses using purified B1 and B0b indicated that they interact dynamically with a single array of telomeric repeats. Furthermore, functional assays demonstrated that B1 and B0b bind with telomeric repeats in a tandem fashion and protect them from a nuclease and promote telomerase activity. A2/B1 proteins, especially B1 and B0b, may function as telomeric ssDNA-binding proteins in cancer and reproductive cells. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11162566     DOI: 10.1006/bbrc.2000.4173

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

Review 1.  Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged.

Authors:  Charles J David; James L Manley
Journal:  Genes Dev       Date:  2010-11-01       Impact factor: 11.361

2.  Establishment of a new method, transcription-reverse transcription concerted reaction, for detection of plasma hnRNP B1 mRNA, a biomarker of lung cancer.

Authors:  Akemi Sato; Naoko Sueoka-Aragane; Juichi Saitoh; Kazutoshi Komiya; Takashi Hisatomi; Rika Tomimasu; Shinichiro Hayashi; Eisaburo Sueoka
Journal:  J Cancer Res Clin Oncol       Date:  2008-05-07       Impact factor: 4.553

3.  In-vitro dual binding activity of a evolutionarily related subgroup of hnRNP proteins.

Authors:  Antonella Bandiera; Nevenka Medic; A Akintunde Akindahunsi; Giorgio Manzini
Journal:  Mol Cell Biochem       Date:  2005-01       Impact factor: 3.396

4.  Histochemical mapping of hnRNP A2/B1 in rat brain after ischemia-reperfusion insults.

Authors:  Yichen Liu; Yan Gao; Yan Wu; Yonghong Wu; Hangyan Wang; Chenggang Zhang
Journal:  J Histochem Cytochem       Date:  2010-04-26       Impact factor: 2.479

5.  Long noncoding RNA in genome regulation: prospects and mechanisms.

Authors:  Tiffany Hung; Howard Y Chang
Journal:  RNA Biol       Date:  2010-09-01       Impact factor: 4.652

6.  Distinct domains in the CArG-box binding factor A destabilize tetraplex forms of the fragile X expanded sequence d(CGG)n.

Authors:  Pnina Weisman-Shomer; Esther Cohen; Michael Fry
Journal:  Nucleic Acids Res       Date:  2002-09-01       Impact factor: 16.971

7.  HnRNP A2/B1 proteins in nontumorous alveolar cells.

Authors:  H Satoh; H Ishikawa; H Kamma; Y T Yamashita; K Sekizawa
Journal:  Lung       Date:  2003       Impact factor: 2.584

8.  Vault poly(ADP-ribose) polymerase is associated with mammalian telomerase and is dispensable for telomerase function and vault structure in vivo.

Authors:  Yie Liu; Bryan E Snow; Valerie A Kickhoefer; Natalie Erdmann; Wen Zhou; Andrew Wakeham; Marla Gomez; Leonard H Rome; Lea Harrington
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

9.  Identification of hub genes and potential molecular mechanisms of chickpea isoflavones on MCF-7 breast cancer cells by integrated bioinformatics analysis.

Authors:  Jia Wang; Hao Yu; Abulimit Yili; Yanhua Gao; Linlin Hao; Haji Akber Aisa; Songcai Liu
Journal:  Ann Transl Med       Date:  2020-02

10.  Telomerase confers resistance to caspase-mediated apoptosis.

Authors:  Yira Bermudez; Diana Erasso; Nicole C Johnson; Michelle Y Alfonso; Nancy E Lowell; Patricia A Kruk
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.